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Abstract
The Rev protein of the human immunodeficiency virus (HIV) facilitates the nuclear export of intron
containing viral mRNAs allowing formation of infectious virions. Rev traffics through the nucleolus
and shuttles between the nucleus and cytoplasm. Rev multimerization and interaction with the
export protein CRM1 takes place in the nucleolus. To test the importance of Rev nucleolar
trafficking in the HIV-1 replication cycle, we created a nucleolar localizing Rev Response Element
(RRE) decoy and tested this for its anti-HIV activity. The RRE decoy provided marked inhibition of
HIV-1 replication in both the CEM T-cell line and in primary CD34+ derived monocytes. These
results demonstrate that titration of Rev in the nucleolus impairs HIV-1 replication and supports a
functional role for Rev trafficking in this sub-cellular compartment.
Background
HIV-1 gene expression is finely regulated [1]. Transcrip-
tion from the HIV-1 long terminal repeat (LTR) produces
a full length RNA of 9 Kb from which several mRNAs are
then generated by splicing (the 4 Kb singly spliced and 2
Kb fully spliced RNAs) [1]. While the fully spliced RNAs
are exported to the cytoplasm, where they are translated
into the regulatory and accessory proteins, the late struc-
tural proteins and reverse transcriptase (RT) are derived
from unspliced or singly spliced RNAs which are trans-
ported to the cytoplasm only upon binding of Rev to the
Rev Responsive Element (RRE), which is contained in the
env coding region [1]. Rev is an 18kDa protein that local-
izes to both the nucleus and nucleolus [2-4]. It contains a
nuclear export signal (NES) as well as a nuclear import sig-
nal (NLS) that allow nuclear/nucleolus-cytoplasmic shut-
tling properties [5,6]. The NES signal of Rev is recognized
by the cellular export factor CRM1, which mediates the
nuclear-cytoplasmic export of Rev bound RNAs [7,8].
Expression of Rev in human cells induces re-localization
of CRM1 and some nucleoporins (Nup98 and Nup214)
into the nucleolus [9]. Recently, by the use of in vivo fluo-
rescence resonance energy transfer (FRET), multimeriza-
tion of Rev-GFP and BFP fusion proteins has been shown
to occur in the nucleoli of HeLa cells [10]. These observa-
tions suggest that the nucleolar trafficking of Rev may be
critical for Rev mediated export. To test this hypothesis we
used a nucleolar localized decoy that contains the Rev
binding element (RBE) [11-14] to sequester Rev within
this sub-cellular compartment and test its ability to
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inhibit HIV-1 replication. The well-characterized U16
small nucleolar RNA (snoRNA) [15] was used to direct
nucleolar delivery of the RBE.
In the present study we demonstrate that stable expression
of the U16-RBE chimeric RNA in cultured T-cells and pri-
mary monocytes confers strong inhibition of viral replica-
tion. These data provide strong evidence that the
nucleolar localization of Rev is critical for its functional
role in HIV-1 replication and identifies a novel mecha-
nism for inhibition of HIV replication.
Materials and methods
Plasmid constructs
The U16RBE DNA was prepared synthetically as previ-
ously described [14]. The Rev Binding Element (RBE) was
inserted in the U16 snoRNA sequence by replacing the
apical loop []. The U16RBE sequence was then subcloned
within the SalI and XbaI sites of the pTZU6+1 expression
cassette [16] generating the pTZU16-RBE clone. The
BamHI and XbaI cleaved fragment from the pTZU16-RBE
construct was first filled in with the DNA polymerase Kle-
now fragment and then inserted in the NheI site of the
pBabe puro retroviral vector (in the U3 region of the
3'LTR, Fig. 1A) giving rise to the pBabe/U16RBE clone
(Fig. 1B). The U6 promoter-U16RBE was also cloned into
a StuI site in the U3 region of the MND/eGFP Banshee ret-
roviral vector 3'LTR (Fig. 1C), generating the MND/eGFP
U16RBE construct (Fig. 1D).
Cell culture
HEK 293, CEM and the PG13 packaging cells were main-
tained as previously described [17]. Transient transfec-
tions were carried out using a Calcium Phosphate DNA
precipitation kit in accordance with the manufacturer's
protocol (GIBCO/BRL, Invitrogen). Briefly, 1 × 106 HEK
293 cells were plated one day prior to transfection. The
transfection was carried out using 2–10 µg of plasmid
DNA.
Packaging cell line
PG13 was used for packaging of the pBabe/U16RBE and
MND/EGFP U16RBE constructs [17].
CD34+ cell isolation and transduction procedures
CD34+ cells were isolated from fresh umbilical cord
blood using anti-CD34+ antibody-coupled magnetic
beads (Milteny Biotech, Auburn, CA). Sorted CD34+ cells
(purity was above 90% as determined by FACS analysis)
were cryopreserved until use for transductions by the viral
vectors.
One day prior to transduction, CD34+ cells were thawed
rapidly at 37°C, washed and plated at a concentration of
2 × 105 onto Retronectin (Takara, Japan) coated 25 cm2
flasks. The Retronectin concentration for coating was 20
µg/cm2. The CD34+ cells were then pre-stimulated in 5 ml
of cytokine media: Iscove's Modified Dulbecco's Media
(IMDM – Bio Whittaker, Walkersville, MD), with 20%
FBS, 100 U/ml Penicillin, 0.1 mg/ml Streptomycin
(Sigma, St. Louis), 2 mM Glutamine (Sigma, St. Louis), IL-
3 (10 ng/ml), IL-6 (10 ng/ml), and SCF (10 ng/ml) (R&D
Systems, Minneapolis, Minnesota). After 24 hours of pre-
stimulation, the media was changed and the CD34+ cells
were exposed to the retroviral vector supernatants (MND/
eGFP, MND/eGFP U16RBE and Mock). 50% percent ret-
roviral vector supernatant and 50% 2 × cytokine media
were used in a total volume of 10 ml per 25 cm2 flask. The
2 × cytokine media has the same composition as the
cytokine media but the growth factor concentrations are
doubled (20 ng/ml for all cytokines). After 24 hours of
infection, the cells were centrifuged, the media removed,
and the cells exposed to fresh retroviral supernatant and
cytokine media in a total volume of 10 ml.
This process was repeated one more time, leading to 3
rounds of transduction.
After 3 rounds of transduction, CD34+ cells were immedi-
ately plated into a Colony Forming Units assay (CFU-
assay) or Long Term Bone Marrow Cultures (LTBMCs).
Colony Forming Unit assays
1 × 103 and 2 × 103 transduced CD34+ cells from each vec-
tor arm were plated into 1 ml semi-solid methylcellulose
media (Methocult, Stem Cell Technologies, Vancouver,
Canada). After 14 days, colonies were counted and dis-
criminated into Burst Forming Units Erythroid (BFU-E),
Granulocyte-Macrophage Colony Forming Units (CFU-
GM) and Granulocyte- Erythroid- Macrophage- Meg-
akaryocyte (CFU-GEMM) Colony Forming Units. The col-
onies for each vector arm were added and the data
expressed as a total colony count per group.
Long term bone marrow cultures
Transduced CD34+ cells were plated into 25 cm2 flasks
onto a layer of irradiated normal human bone marrow
stroma in cytokine media. The cytokine concentrations
for SCF, IL-3 and IL-6 were 10 ng/ml each.
Normal human bone marrow was purchased from Bio
Whittaker (Cambrex Bio Science Inc. Rockland, MD), 5
ml were plated directly into Dulbecco's Modified Eagle
Media (Cambrex Bio Science) with 10% Fetal Bovine
Serum (GIBCO) in a 75 cm2 flask. Bone marrow cells were
allowed to adhere overnight. Media and floating cells
were removed, and fresh media were added. Stromal cells
were allowed to expand for about 4 weeks. After expan-
sion, stromal cells were trypsinised and cryopreserved forAIDS Research and Therapy 2006, 3:13 http://www.aidsrestherapy.com/content/3/1/13
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later use, or irradiated (2000 rads) and plated into 25 cm2
flasks for LTBMCs at a density of 1 × 105 cells per flask.
CD34+ cells were allowed to expand in the stromal cul-
ture flasks. Cell samples were taken for eGFP FACS analy-
sis 2 days after plating to assess the transduction
frequency.
10 days after plating, cultures were depleted of the floating
cell population, which was used for eGFP cell sorting and
subsequent HIV-challenge. After depletion, the remaining
cell fraction in the stroma flasks regenerated a high
number of floating cells within 14 days. After 6 weeks of
LTBMC propagation, a final FACS analysis was performed
to assess eGFP expression.
eGFP sorting and propagation of sorted CD34+ progenitor 
derived cell populations
CD34+ derived cells were sorted for eGFP expression in a
MoFLO (Cytomation) cell sorter into 6 well plates con-
taining a layer of irradiated normal human stroma and 2
× cytokine media (20 ng/ml all cytokines). Cells were
expanded in these 6 well plates for approximately 5 days.
After expansion, cells were removed from the wells and
divided into 2 fractions: 1 × 105 cells for eGFP FACS anal-
ysis (purity check), and 1 × 106 cells for HIV-challenge.
Retroviral constructs Figure 1
Retroviral constructs. (A) Schematic representation of the pBabe puro retroviral vector [22]. (B) Schematic representation 
of the pBabe/U16RBE construct. The PTZU16-RBE cassette was inserted in the U3 region of the 3'LTR, with the U6 promoter. 
Transcription is oriented in the same direction as the RNA pol II LTR and SV40 promoters. (C) Schematic representation of 
the MND/eGFP retroviral vector. (D) Schematic representation of the MND/eGFP U16RBE construct. The PTZU16-RBE cas-
sette was inserted in the U3 region of the 3'LTR, with the U6 promoter transcribing in the same orientation as the RNA pol II 
LTR and SV40 promoters.AIDS Research and Therapy 2006, 3:13 http://www.aidsrestherapy.com/content/3/1/13
Page 4 of 9
(page number not for citation purposes)
HIV-challenge
CEM cells (2.5 × 105) derived from stably transduced
clones were infected with HIV-1NL4-3  as previously
described [18]. For CD34+ derived monocytes, 1 × 106
sorted CD34+ cells were transferred into 12 × 75 tubes,
centrifuged, and resuspended in 100 µl of 2 × cytokine
media. 100 µl of HIV-1 JRFL with a titer of 1 × 105 /ml was
added to each challenge tube, resulting in a multiplicity of
infection (m.o.i.) of 0.01. Cells were incubated at 37°C
and 5% CO2 for 3 hours and then 200 µl of 2 × cytokine
media were added to each tube and the cells were incu-
bated overnight.
On the following day, cells were washed 4 times and
plated into 25 cm2 flasks onto a layer of irradiated S17
cells (kindly provided by Kenneth Dorshkind, UCLA), in
1 × cytokine media in a total volume 10 ml. The cultures
were propagated for 28 days and samples were taken
weekly. Infections were all performed in duplicate or trip-
licate.
HIV-1 p24 evaluation
The p24 analyses were performed using the HIV-1 p24
antigen capture assay kit (Science Applications Interna-
tional Corp. Frederick) for the experiment in Fig. 3 and a
Beckman/Coulter p24 assay kit (Beckman, FL) for the
experiments in Fig. 4B.
Stably transduced CEM clones expressing the U16RBEdecoy Figure 2
Stably transduced CEM clones expressing the U16RBEdecoy. The CEM cells were first transduced with the pBabe 
constructs and then selected for Puromycin resistance. 
From the resulting pooled population single clones were selected by limiting dilution. Total RNA isolated from the single 
clones was electrophoresed either in a 6% polyacrylamide-7M Urea (A) or 1.2 % Agarose formaldehyde (B) gels.  The electro-
phoresed RNAs were blotted onto a nylon filter followed by hybridization with specific probes (see Material and Methods).AIDS Research and Therapy 2006, 3:13 http://www.aidsrestherapy.com/content/3/1/13
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RNA extraction and Northern Blot analysis
Total RNA was isolated as previously described [18].
Northern Blot analyses were performed by electrophores-
ing the isolated total RNA either in a 6% polyacrylamide-
7M Urea gel or in a 1. % Agarose formaldehyde gel fol-
lowed by blotting onto a nylon filter. To simultaneously
detect the endogenous U16 snoRNA and the U16RBE
RNA, a probe complementary to the 3' end of the U16 was
used (Fig. 2A). To detect only the U16RBE a probe com-
plementary to the RBE sequence was used (Fig. 2B). As
loading controls probes specific for tRNA3 
Lys or the β-
Actin were used (Fig. 2).
Results
Nucleolar expression of the Rev Binding Element (RBE)
was achieved by substitution of the apical loop of the U16
small nucleolar RNA (snoRNA) with the RBE sequence as
previously described [14]. The RBE domain is located
within the Rev responsive element (RRE) sequence
(within stem-loop IIB, which contains a purine rich "bub-
ble"). Rev has a high binding affinity for this element [11-
13]. U16 is a member of the C/D box class of snoRNAs
that are primarily involved in post-transcriptional modifi-
cations (2' O-methylation) of rRNA molecules [19]. In
order to achieve expression of U16RBE in human cells,
the chimeric gene was cloned downstream the U6 small
nuclear RNA Pol III promoter (clone PTZU16-RBE; [14]).
Intracellular expression and nucleolar compartmentaliza-
tion of the U16RBE RNA in 293 cells has been previously
demonstrated [14].
To test the intracellular efficacy of the U16RBE against
HIV-1 replication, the PTZU16-RBE expression cassette
was inserted into the U3 region of the pBabe puro retrovi-
ral vector (clone pBabe/U16RBE, Fig. 1). The resulting
vector pBabe/U16RBE was then used to transduce the
human CEM T cell line. The U6-U16RBE gene inserted
within the U3 region of the retroviral vector should be
duplicated within the 5' LTR following reverse transcrip-
tion and integration. Single clones stably expressing
U16RBE in vivo activity Figure 3
U16RBE in vivo activity. Some of the CEM clones expressing the U16RBE RNA decoy along with the parental CEM cells 
were challenged with HIV-1 NL4-3 at an m.o.i of 0.001.CEM clones expressing either a nucleolar anti-HIV-1 hammerhead 
ribozyme wt (U16Rz wt 11) or the mutant disabled mutant version (U16Rz mutant 4) were used respectively as positive and 
negative controls for inhibition of HIV-1 infection [18]. On days 1, 10 and 17 day post-infection the supernatants from these 
cell cultures were collected and assayed for HIV-1 p24Gag accumulation. The data presented represent an average of two inde-
pendent challenge experiments, and the standard errors for each point are around 5%AIDS Research and Therapy 2006, 3:13 http://www.aidsrestherapy.com/content/3/1/13
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U16RBE were isolated following Puromycin selection.
Northern blot analyses performed using total RNA
extracted from the selected clones showed somewhat var-
ying levels of expression of the RNA decoy (Fig. 2A).
Transcription of the U16RBE could originate from the U6
promoter as well as from the 5' LTR and internal SV40
polII promoters (Fig. 1B). In order to discern the origins
of the major transcripts, a Northern blot analysis was per-
formed on RNA separated in a 1.2% Agarose-Formalde-
heyde gel to resolve both long and short transcripts. As
shown in Fig. 2B, more than 95% of the U16RBE RNA was
of a size corresponding to a U6 promoter-driven tran-
script. Upon longer exposure (data not presented) tran-
scripts of a size originating from the LTR and SV40
promoters can be seen. These results suggest that the
majority of the U16RBE RNAs were derived from the Pol
III promoters, with minor amounts originating from the
LTR or SV40 internal promoters. In addition, transcripts
originating from the Pol II promoters that read through
the U16RBE structure may be subject to processing by the
snoRNA processing machinery. It is not possible to deter-
mine how much, if any processing such as this takes place.
We next tested the anti-HIV-1 activity of the U16RBE
decoy by challenging several of the stably transduced CEM
clones expressing the U16RBE RNA with the HIV-1 NL4-3
strain using a multiplicity of infection of 0.001. As posi-
tive and negative controls for this experiment we also
challenged CEM clones expressing either a nucleolar
localizing anti-HIV-1 wild type ribozyme (wt) or its disa-
bled mutant version (clones U16Rz wt and mutant; [18]).
At days 1, 10 and 17 post-infection the cell culture super-
natants were collected and assayed for the release of the
viral p24Gag protein. As shown in Fig. 3, the controls
(parental CEM cells and a CEM clonal line expressing the
mutant U16Rz) were highly permissive to replication dur-
ing the 17 days of analysis. In contrast, all the clonal lines
expressing U16RBE and the one expressing U16Rz wt
were highly resistant to the HIV-1 challenge.
CD34+ progenitor cell derived monocytes stably expressing U16RBE are resistant to HIV-1 infection Figure 4
CD34+ progenitor cell derived monocytes stably expressing U16RBE are resistant to HIV-1 infection. CD34+ 
cells isolated from human cord blood were first transduced with either the parental MND/eGFP vector or the MND/eGFP 
U16RBE and then sorted for eGFP expression. (A) total RNA isolated from the eGFP sorted, transduced CD34+ cells was 
electrophoresed in a 6% polyacrylamide-7M Urea gel and blotted onto a nylon filter. Hybridizations were performed using a 
probe complementary to the 3' end of the U16 snoRNA and a probe specific for the tRNA3
Lys used as a loading control. (B) 
Parental CD34+ cells along with the transduced and eGFP sorted CD34+ cells were challenged with HIV-1 JFRL using an m.o.i. 
of 0.01. On days 1, 7, 14, 21 and 28 days post-infection the accumulation of the viral p24gag antigen was assayed. The data pre-
sented represent an average of two independent challenge experiments, and the standard errors for each point are approxi-
mately 5%AIDS Research and Therapy 2006, 3:13 http://www.aidsrestherapy.com/content/3/1/13
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To test the anti-HIV-1 activity of U16RBE in more clini-
cally relevant cells, the PTZU16-RBE cassette was inserted
within the U3 region of the 3'LTR of the MND/eGFP ret-
roviral vector (Fig. 1C). This vector allows use of eGFP
expression to monitor transduction. The recombinant
vector was transduced into human CD34+ progenitor
cells purified from umbilical cord blood. Cells were prop-
agated under cell culture conditions that allow differenti-
ation into CD4+ monocytes. Cell counts after pre-
stimulation and transduction were similar for both mock
and recombinant vectors, with cell viability greater than
90% and cell expansion about two-fold in all cases (data
not presented). To assess potential toxicities of the vec-
tors, colony assays were carried out using the transduced
CD34+ cells. Although some differences in colony form-
ing numbers were observed between the three samples
(Table 1A), in our hands these small differences are not
significant, suggesting no overt toxicity of the U16RBE
expression.
The transduction efficiency (TD) was assessed by FACS
analyses (monitoring eGFP expression) of the cells at days
1 and 45 post transduction (Table 1B). The TD was
between 3 and 6 % of the gated population on day 1 post-
transduction as determined by measuring eGFP expres-
sion. After 45 days, expression of eGFP dropped to less
than 1%. The relatively low level of transduction effi-
ciency is a consequence of the vector preparation and can
vary significantly from experiment to experiment. The
drop in eGFP expression is due to epigenetic silencing of
the LTR driving EGFP in this vector. The Pol III promoter
expression does not diminish during this time (H.Li, D.
Castanotto and J. Rossi-unpublished observations).
Ten days after transduction the cells were sorted for eGFP
expression. The sort purity was checked 5 days later with
no significant differences among the various vector trans-
duced cells (data not shown). Northern Blot analyses, car-
ried out on total RNAs isolated from the eGFP sorted
CD34+ derived cells, showed readily detectable levels of
the U16RBE RNA, which were comparable to the levels of
the endogenous U16 snoRNA (Fig. 4A).
The sorted cells were next challenged on the day of FACS
analysis with the M-tropic HIV-1 JRFL isolate at a multi-
plicity of infection of 0.01. On days 1, 7, 14, 21 and 28
post-infection, the supernatants were collected and tested
for p24Gag protein accumulation.
As shown in figure 4B, while the mock and the eGFP
sorted CD34+ cells transduced with the parental MND/
EGFP vector were highly permissive to viral replication,
cells expressing the MND/eGFP U16RBE resulted in over
4 logs of inhibition out to 28 days post infection.
Discussion
We previously exploited the use of the U16 snoRNA as a
vector for the nucleolar delivery of therapeutic anti-HIV
ribozyme and TAR decoy RNAs [17,18]. It was previously
demonstrated that substitution of the apical loop of U16
with the RBE sequence gave rise to an RNA decoy that
localized in the nucleoli of 293 cells and was able to inter-
act with Rev in X. laevis oocytes [14]. In these studies the
interaction of the U16RBE decoy with Rev induced the re-
localization of the decoy from the nucleus to the cyto-
plasm. Although we were not able to follow this traffick-
ing in the present experiments, we assume this re-
localization also took place in the T- cells and monocytes
used in the present studies.
Our primary interest in the present studies was whether or
not the U16RBE would sequester Rev sufficiently to
inhibit HIV-1 replication in human CEM T-cells and in
primary monocytes derived from hematopoietic progeni-
tor CD34+ cells.
To test this possibility we inserted the U6 expression cas-
sette containing the U16RBE sequence within the U3
Table 1: CD34+ cell transduction with MND constructs. (A). 1 × 103 and 2 × 10 3 transduced CD34+ cells transduced with the control or 
U16RBE expression vectors were plated into 1 ml semi-solid methylcelluose media. After 14 days, colonies were counted and analyzed 
for Erythroid-Burst Forming Units (BFU-E), Granulocyte Macrophage -Colony Forming Units (CFU-GM) and Granulocyte Erythroid 
Macrophage Megakaryocyte Colony Forming Units (CFU-GEMM). (B) After transduction CD34+ cells were allowed to expand in 
stroma flasks, and cell samples were taken for eGFP FACS analysis 1 and 45 days after plating to assess transduction frequency. The 
loss of eGFP expression with time is a consequence of epigenetic silencing of the MND LTR (Castanotto, Li and Rossi, unpublished 
results).
(A) CD34+ CFU Count Total
BFU-E CFU-GM CFU-GEMM
MOCK 287 782 23
MND/eGFP 327 856 12
MND/U 16RBE 161 736 8
(B) CD34+ Transduction efficiency
% eGFP 1 day post TD %eGFP 45 day post td
MND/eGFP 5.98 0.79
MND/U 16 RBE 3.24 0.42AIDS Research and Therapy 2006, 3:13 http://www.aidsrestherapy.com/content/3/1/13
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region of the 3'LTR of two different retroviral vectors,
pBabe puro and MND/eGFP (giving rise to pBabe/
U16RBE and MND/eGFP U16RBE constructs, Fig. 1).
Using the pBabe/U16RBE plasmid we first transduced the
CEM T cell line and selected Puromycin resistant clones
stably expressing the U16RBE (Fig. 2). We challenged
some of these clones with HIV-1 NL4-3 and demonstrated
that over a period of 17 days the decoy conferred near
complete inhibition of viral replication (Fig. 3). To further
test the U16RBE RNA as a possible candidate for hemat-
opoietic stem cell gene therapy for HIV-1, the anti-HIV-1
activity of the U16RBE decoy was tested in human umbil-
ical cord blood CD34+ derived monocytes. The CD34+
cells were transduced with either the MND/eGFP or
MND/eGFP U16RBE constructs and allowed to differenti-
ate into monocytes in culture. FACS sorted, transduced
monocytes were challenged with HIV-1 JRFL at a multiplic-
ity of infection of 0.01 and the infection was monitored
for a period of 28 days (Fig. 4B). While the controls (mock
and MND/eGFP transduced CD34+ cells) readily sup-
ported viral replication resulting in secretion of µg quan-
tities of p24Gag, the CD34+ derived cells expressing the
U16RBE showed four logs of p24 inhibition even after 28
days post infectious challenge (Fig. 4B).
In conclusion, we have demonstrated that the nucleolar
localizing U16RBE decoy is a potent inhibitor of the HIV-
1 replication. These results suggest that this inhibitor
could be a candidate for anti-HIV gene therapy. The decoy
could be used alone or in combination with other potent
therapeutic RNAs, such as anti-HIV short hairpin RNAs
[20]. Rev is essential for HIV-1 structural gene expression
and full length viral RNA packaging and consequently
sequestering of this protein via the decoy resulted in
strong anti-HIV activity. It is highly likely that the decoy-
Rev complex traffics to the cytoplasm as was observed in
the Xenopus oocytes [14] since Crm1 is the transport car-
rier in both organisms. Targeting Rev in the nucleolus
allows capturing of this protein prior to its interaction
with the viral RRE. Furthermore, this strategy is unlikely to
result in emergence of viral Rev mutants that can no
longer bind the decoy since these would also be defective
in binding to the viral RBE. In such a dual component sys-
tem, mutants in Rev would have to co-evolve with altered
forms of the RBE to escape the inhibitory activity of the
decoy. Since the U16RBE is encoded in a small gene, it
should be easy to combine this with other antiviral RNAs
such as shRNAs. A combinatorial approach, which
includes the U16RBE, should increase the overall antiviral
potency [21] and further minimize the occurrence of viral
escape mutants. Although the nucleolar localization of
some HIV proteins [23], and perhaps of some classes of
HIV RNAs [18], has been demonstrated, the functional
role of this cellular localization is poorly understood.
Concerning Rev, it has been suggested that the nucleoli
could be a "storage site" for the protein [24] and in some
cases it has been reported that Rev can function without
nucleolar localization [25,26]. At the same time, it is note-
worthy to mention that when Rev is expressed ectopically
it localizes primarily within the nucleoli of human cells
[2-4] where it multimerizes [10] and relocates CRM1 and
some nucleoporins [9]. Rev multimerization is a critical
event for the nucleocytoplasmic transport of incompletely
spliced and unspliced HIV RNAs, and the association with
CRM1 and nucleoporins is probably critical for its own
nuclear export. These latter observations underline a cru-
cial role of the nucleolus in Rev function and therefore in
the HIV-1 replicative cycle. One possibility is that use of
the Crm1 export pathway provides a mechanism for
unspliced HIV RNAs to escape the nonsense mediated
decay mechanism, although this is only a hypothetical
explanation at this time. The importance of nucleolar traf-
ficking of Rev and HIV is strengthened by the data
reported here and by previously published data wherein
we demonstrated that a nucleolar localizing TAR decoy
[17] as well as a nucleolar localizing anti-HIV-1 hammer-
head ribozyme [18] are both potent inhibitors of HIV-1
replication.
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